Table 1.
Patient characteristics and summary of treatment efficacy
| Variable | Level | N = 20 | % |
|---|---|---|---|
| Gender | F | 7 | 35.0 |
| M | 13 | 65.0 | |
| Race | White | 16 | 80.0 |
| Black | 4 | 20.0 | |
| Age (years) | Mean | 63.40 (10.67) | |
| Median | 63 (48–84) | ||
| Age (years) | <65 | 10 | 50.0 |
| ≥65 | 10 | 50.0 | |
| ECOG performance status | 0 | 2 | 10 |
| 1 | 13 | 65 | |
| 2 | 5 | 25 | |
| No of prior therapies | 1a | 6 | 30 |
| 2b | 6 | 30 | |
| 3c | 7 | 35 | |
| 4d | 1 | 5 | |
| Best response | PD | 15 | 88.2 |
| SD | 2 | 11.8 | |
| Time to progression (TTP) | Mean | 6.26 (3.9) | |
| Median | 7 (1–17) |
aPlatinum/etoposide; platinum etoposide/XRT, platinum/etoposide/GDC-049
bTopotecan, oral etoposide, platinum/irinotecan, platinum/etoposide, topotecan/aflibercept; gemcitabine, paclitaxel
cPlatinum etoposide, platinum/irinotecan, topotecan, irinotecan
dIrinotecan